Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2007
Event: Entry into a Material Definitive Agreement with Dr. Aaron Ciechanover for appointment to the Scientific Advisory Board.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific contractual agreement.
Material Changes
The Company entered into a Scientific Advisory Board Agreement with Dr. Aaron Ciechanover, a Nobel Laureate, effective August 5, 2007. The agreement outlines his role in providing strategic and business development advice, attending regulatory meetings (including with the FDA), and participating in Scientific Advisory Board meetings.
Agreement Terms and Compensation
- Cash Compensation: Annual fee of $18,000, payable in two semi-annual installments.
- Equity Compensation: Grant of 8,000 restricted shares of common stock under the 2006 Stock Incentive Plan.
- Vesting Schedule:
- 25% vests on the one-year anniversary of the grant date.
- Remaining 75% vests monthly in 36 equal installments thereafter.
- Duration: The agreement remains in effect until terminated by either party.
Investor Verification Checklist
- Verify the impact of the 8,000 restricted share grant on total outstanding shares and potential dilution.
- Review the Company's 2006 Stock Incentive Plan to confirm the availability of shares for this grant.
- Assess the strategic value of Dr. Ciechanover's specific expertise relative to the Company's current pipeline and regulatory challenges.
- Confirm the total annual cash obligation ($18,000) against the Company's current cash burn rate.